Sorafenib-induced pancreatitis

被引：24

作者：

Amar, Surabhi ^{[1
]}

Wu, Kevin J. ^{[1
]}

Tan, Winston W. ^{[1
]}

机构：

[1] Mayo Clin, Coll Med, Jacksonville, FL USA

来源：

MAYO CLINIC PROCEEDINGS | 2007年 / 82卷 / 04期

关键词：

D O I：

10.4065/82.4.521

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：521 / 521

页数：1

相关论文

共 5 条

[1]

Escudier B, 2005, J CLIN ONCOL, V23, p1093S

[2] PLATELET-DERIVED GROWTH-FACTOR AND TRANSFORMING GROWTH FACTOR-BETA ENHANCE TISSUE-REPAIR ACTIVITIES BY UNIQUE MECHANISMS [J].

PIERCE, GF ;

MUSTOE, TA ;

LINGELBACH, J ;

MASAKOWSKI, VR ;

GRIFFIN, GL ;

SENIOR, RM ;

DEUEL, TF .

JOURNAL OF CELL BIOLOGY, 1989, 109 (01) :429-440

[3] Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors [J].

Strumberg, D ;

Richly, H ;

Hilger, RA ;

Schleucher, N ;

Korfee, S ;

Tewes, M ;

Faghih, M ;

Brendel, E ;

Voliotis, D ;

Haase, CG ;

Schwartz, B ;

Awada, A ;

Voigtmann, R ;

Scheulen, ME ;

Seeber, S .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :965-972

[4] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].

Wilhelm, SM ;

Carter, C ;

Tang, LY ;

Wilkie, D ;

McNabola, A ;

Rong, H ;

Chen, C ;

Zhang, XM ;

Vincent, P ;

McHugh, M ;

Cao, YC ;

Shujath, J ;

Gawlak, S ;

Eveleigh, D ;

Rowley, B ;

Liu, L ;

Adnane, L ;

Lynch, M ;

Auclair, D ;

Taylor, I ;

Gedrich, R ;

Voznesensky, A ;

Riedl, B ;

Post, LE ;

Bollag, G ;

Trail, PA .

CANCER RESEARCH, 2004, 64 (19) :7099-7109

[5]

2006, NEVAXAR SORAFENIB PA